nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2022-4-96-102nnp-1868Research ArticleREVIEWSОБЗОРЫCognitive impairment in patients with coronavirus infectionКогнитивные нарушения у пациентов, перенесших коронавирусную инфекциюhttps://orcid.org/0000-0001-6624-5500СтарчинаЮ. А.StarchinaY. A.

Юлия Александровна Старчина119021, Москва, ул. Россолимо, д. 11, стр. 1

Yulia Aleksandrovna Starchina119021, Moscow, Rossolimo St., 11, Build. 1

yul-starchina@yandex.ruhttps://orcid.org/0000-0001-5827-9428КосивцоваО. В.KosivtsovaO. V.

119021, Москва, ул. Россолимо, д. 11, стр. 1

119021, Moscow, Rossolimo St., 11, Build. 1

Кафедра нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияDepartment of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation20222408202214496102Copyright © Starchina Y.A., Kosivtsova O.V., 20222022Старчина Ю.А., Косивцова О.В.Starchina Y.A., Kosivtsova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1868

The pathogenesis of the development of cognitive impairment (CI) associated with the SARS-CoV-2 virus is complex and includes the direct neurotoxic effect of the virus, vascular, disimmune factors, artificial lung ventilation, and adverse psychological consequences of social isolation. The relationship between CI and SARS-CoV-2 infection appears to be two-way: patients with premorbid CI have a higher risk of infection, severe illness, and death; on the other hand, past infection with SARS-CoV-2 may stimulate the clinical onset and progression of CI, including Alzheimer's disease. For the treatment of severe CI after COVID-19, memantine (akatinol memantine) is recommended.

Патогенез развития когнитивных нарушений (КН), ассоциированных с вирусом SARS-CoV-2, сложен и включает прямое нейротоксическое влияние вируса, сосудистые, дизиммунные факторы, пребывание на искусственной вентиляции легких и неблагоприятные психологические последствия социальной изоляции. Связь между КН и инфекцией SARS-CoV-2, по-видимому, двусторонняя: пациенты с преморбидными КН имеют более высокий риск инфицирования, тяжелого течения заболевания и смерти; с другой стороны, перенесенная инфекция SARS-CoV-2 может стимулировать клинический дебют и прогрессирование КН, включая болезнь Альцгеймера. Для лечения выраженных КН после COVID-19 рекомендовано использовать мемантин (акатинол мемантин).

коронавирусCOVID-19деменцияболезнь Альцгеймеракогнитивные нарушениямемантинcoronavirusCOVID-19dementiaAlzheimer's diseasecognitive impairmentmemantineСтатья спонсируется компанией «Мерц Фарма».This article has been supported by Merz Pharma.ReferencesWorld Health Organization. Available from: https://covid19.who.int/ (accessed 01.07.2022).World Health Organization. Available from: https://covid19.who.int/ (accessed 01.07.2022).Tay MZ, Poh CM, Renia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Jun;20(6):363-74. doi:10.1038/s41577-020-0311-8. Epub 2020 Apr 28.Tay MZ, Poh CM, Renia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Jun;20(6):363-74. doi:10.1038/s41577-020-0311-8. Epub 2020 Apr 28.Thakur B, Dubey P, Benitez J, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021 Apr 20;11(1):8562. doi:10.1038/s41598-021-88130-wThakur B, Dubey P, Benitez J, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021 Apr 20;11(1):8562. doi:10.1038/s41598-021-88130-wBianchetti A, Rozzini R, Guerini F, et al. Clinical Presentation of COVID19 in Dementia Patients. J Nutr Health Aging. 2020;24(6):560-2. doi:10.1007/s12603-020-1389-1Bianchetti A, Rozzini R, Guerini F, et al. Clinical Presentation of COVID19 in Dementia Patients. J Nutr Health Aging. 2020;24(6):560-2. doi:10.1007/s12603-020-1389-1Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020 Jul;87:18-22. doi:10.1016/j.bbi.2020.03.031. Epub 2020 Mar 30.Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020 Jul;87:18-22. doi:10.1016/j.bbi.2020.03.031. Epub 2020 Mar 30.Toniolo S, Scarioni M, Di Lorenzo F, et al; Management Group of the EAN Dementia and Cognitive Disorders Scientific Panel. Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care. J Alzheimers Dis. 2021;82(3):883-98. doi:10.3233/JAD-210335Toniolo S, Scarioni M, Di Lorenzo F, et al; Management Group of the EAN Dementia and Cognitive Disorders Scientific Panel. Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care. J Alzheimers Dis. 2021;82(3):883-98. doi:10.3233/JAD-210335Zhou J, Liu C, Sun Y, et al. Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study. Brain Behav Immun. 2021 Jan;91:383-92. doi:10.1016/j.bbi.2020.10.019. Epub 2020 Oct 24.Zhou J, Liu C, Sun Y, et al. Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study. Brain Behav Immun. 2021 Jan;91:383-92. doi:10.1016/j.bbi.2020.10.019. Epub 2020 Oct 24.Chang TS, Ding Y, Freund MK, et al; UCLA Health Data Mart Working Group. Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System. medRxiv [Preprint]. 2020 Jul 9:2020.07.03.20145581. doi:10.1101/2020.07.03.20145581Chang TS, Ding Y, Freund MK, et al; UCLA Health Data Mart Working Group. Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System. medRxiv [Preprint]. 2020 Jul 9:2020.07.03.20145581. doi:10.1101/2020.07.03.20145581Herman C, Mayer K, Sarwal A. Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology. 2020 Jul 14;95(2):77-84. doi:10.1212/WNL.0000000000009673. Epub 2020 Apr 28.Herman C, Mayer K, Sarwal A. Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology. 2020 Jul 14;95(2):77-84. doi:10.1212/WNL.0000000000009673. Epub 2020 Apr 28.Atkins JL, Masoli JAH, Delgado J, et al. Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224-30. doi:10.1093/gerona/glaa183Atkins JL, Masoli JAH, Delgado J, et al. Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224-30. doi:10.1093/gerona/glaa183Azarpazhooh MR, Amiri A, Morovatdar N, et al. Correlations between COVID-19 and burden of dementia: An ecological study and review of literature. J Neurol Sci. 2020 Sep 15;416:117013. doi:10.1016/j.jns.2020.117013. Epub 2020 Jul 4.Azarpazhooh MR, Amiri A, Morovatdar N, et al. Correlations between COVID-19 and burden of dementia: An ecological study and review of literature. J Neurol Sci. 2020 Sep 15;416:117013. doi:10.1016/j.jns.2020.117013. Epub 2020 Jul 4.Suarez-Gonzalez A et al. Impact and mortality of COVID-19 on people living with dementia: Cross-country report. 2020. Available from: https://ltccovid.org/wp-content/uploads/2020/08/International-report-onthe-impact-of-COVID-19-on-people-livingwith-dementia-19-August-2020.pdfSuarez-Gonzalez A et al. Impact and mortality of COVID-19 on people living with dementia: Cross-country report. 2020. Available from: https://ltccovid.org/wp-content/uploads/2020/08/International-report-onthe-impact-of-COVID-19-on-people-livingwith-dementia-19-August-2020.pdfKuo CL, Pilling LC, Atkins JL, et al. ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank. J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1801-3. doi:10.1093/gerona/glaa169Kuo CL, Pilling LC, Atkins JL, et al. ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank. J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1801-3. doi:10.1093/gerona/glaa169Cesari M, Proietti M. COVID-19 in Italy: Ageism and Decision Making in a Pandemic. J Am Med Dir Assoc. 2020 May;21(5):576-7. doi:10.1016/j.jamda.2020.03.025. Epub 2020 Apr 1.Cesari M, Proietti M. COVID-19 in Italy: Ageism and Decision Making in a Pandemic. J Am Med Dir Assoc. 2020 May;21(5):576-7. doi:10.1016/j.jamda.2020.03.025. Epub 2020 Apr 1.Alzheimer Europe. Alzheimer Europe position regarding the allocation of scarce medical resources for intensive care services during the COVID-19 pandemic. 2020. Available from: https://www.ceafa.es/files/2020/04/2020-intensive-care-services-during-covid-19-1.pdfAlzheimer Europe. Alzheimer Europe position regarding the allocation of scarce medical resources for intensive care services during the COVID-19 pandemic. 2020. Available from: https://www.ceafa.es/files/2020/04/2020-intensive-care-services-during-covid-19-1.pdfEllul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020 Sep;19(9):767-83. doi:10.1016/S1474-4422(20)30221-0. Epub 2020 Jul 2.Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020 Sep;19(9):767-83. doi:10.1016/S1474-4422(20)30221-0. Epub 2020 Jul 2.Varatharaj A, Thomas N, Ellul MA, et al; CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020 Oct;7(10):875-82. doi:10.1016/S2215-0366(20)30287-X. Epub 2020 Jun 25. Erratum in: Lancet Psychiatry. 2020 Jul 14.Varatharaj A, Thomas N, Ellul MA, et al; CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020 Oct;7(10):875-82. doi:10.1016/S2215-0366(20)30287-X. Epub 2020 Jun 25. Erratum in: Lancet Psychiatry. 2020 Jul 14.Alonso-Lana S, Marquie M, Ruiz A, Boada M. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. Front Aging Neurosci. 2020 Oct 26;12:588872. doi:10.3389/fnagi.2020.588872Alonso-Lana S, Marquie M, Ruiz A, Boada M. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. Front Aging Neurosci. 2020 Oct 26;12:588872. doi:10.3389/fnagi.2020.588872Pinna P, Grewal P, Hall JP, et al. Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline. J Neurol Sci. 2020 Aug 15;415:116969. doi:10.1016/j.jns.2020.116969. Epub 2020 Jun 3.Pinna P, Grewal P, Hall JP, et al. Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline. J Neurol Sci. 2020 Aug 15;415:116969. doi:10.1016/j.jns.2020.116969. Epub 2020 Jun 3.Zarifkar P, Peinkhofer C, Benros ME, Kondziella D. Frequency of Neurological Diseases After COVID-19, Influenza A/B and Bacterial Pneumonia. Front Neurol. 2022 Jun 23;13:904796. doi:10.3389/fneur.2022.904796Zarifkar P, Peinkhofer C, Benros ME, Kondziella D. Frequency of Neurological Diseases After COVID-19, Influenza A/B and Bacterial Pneumonia. Front Neurol. 2022 Jun 23;13:904796. doi:10.3389/fneur.2022.904796Rahman MA, Islam K, Rahman S, Alamin M. Neurobiochemical Cross-talk Between COVID-19 and Alzheimer's Disease. Mol Neurobiol. 2021 Mar;58(3):1017-23. doi:10.1007/s12035-020-02177-w. Epub 2020 Oct 19.Rahman MA, Islam K, Rahman S, Alamin M. Neurobiochemical Cross-talk Between COVID-19 and Alzheimer's Disease. Mol Neurobiol. 2021 Mar;58(3):1017-23. doi:10.1007/s12035-020-02177-w. Epub 2020 Oct 19.Ding Q, Shults NV, Gychka SG, et al. Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer's Disease. Int J Mol Sci. 2021 Feb 8;22(4):1687. doi:10.3390/ijms22041687Ding Q, Shults NV, Gychka SG, et al. Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer's Disease. Int J Mol Sci. 2021 Feb 8;22(4):1687. doi:10.3390/ijms22041687Politi LS, Salsano E, Grimaldi M. Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia. JAMA Neurol. 2020 Aug 1;77(8):1028-9. doi:10.1001/jamaneurol.2020.2125Politi LS, Salsano E, Grimaldi M. Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia. JAMA Neurol. 2020 Aug 1;77(8):1028-9. doi:10.1001/jamaneurol.2020.2125Zubair AS, McAlpine LS, Gardin T, et al. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol. 2020 Aug 1;77(8):1018-27. doi:10.1001/jamaneurol.2020.2065Zubair AS, McAlpine LS, Gardin T, et al. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol. 2020 Aug 1;77(8):1018-27. doi:10.1001/jamaneurol.2020.2065Park MD. Macrophages: a Trojan horse in COVID-19? Nat Rev Immunol. 2020 Jun;20(6):351. doi:10.1038/s41577-020-0317-2Park MD. Macrophages: a Trojan horse in COVID-19? Nat Rev Immunol. 2020 Jun;20(6):351. doi:10.1038/s41577-020-0317-2Fenrich M, Mrdenovic S, Balog M, et al. SARS-CoV-2 Dissemination Through Peripheral Nerves Explains Multiple Organ Injury. Front Cell Neurosci. 2020 Aug 5;14:229. doi:10.3389/fncel.2020.00229Fenrich M, Mrdenovic S, Balog M, et al. SARS-CoV-2 Dissemination Through Peripheral Nerves Explains Multiple Organ Injury. Front Cell Neurosci. 2020 Aug 5;14:229. doi:10.3389/fncel.2020.00229Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020 Nov;16(11):636-44. doi:10.1038/s41582-020-0398-3. Epub 2020 Aug 24.Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020 Nov;16(11):636-44. doi:10.1038/s41582-020-0398-3. Epub 2020 Aug 24.Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020 Nov;19(11):919-29. doi:10.1016/S1474-4422(20)30308-2. Epub 2020 Oct 5.Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020 Nov;19(11):919-29. doi:10.1016/S1474-4422(20)30308-2. Epub 2020 Oct 5.Pensato U, Muccioli L, Cani I, et al. Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy. Ann Clin Transl Neurol. 2021 Apr;8(4):968-79. doi:10.1002/acn3.51348. Epub 2021 Mar 29.Pensato U, Muccioli L, Cani I, et al. Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy. Ann Clin Transl Neurol. 2021 Apr;8(4):968-79. doi:10.1002/acn3.51348. Epub 2021 Mar 29.Meneses G, Cardenas G, Espinosa A, et al. Sepsis: developing new alternatives to reduce neuroinflammation and attenuate brain injury. Ann N Y Acad Sci. 2019 Feb;1437(1):43-56. doi:10.1111/nyas.13985. Epub 2018 Nov 29.Meneses G, Cardenas G, Espinosa A, et al. Sepsis: developing new alternatives to reduce neuroinflammation and attenuate brain injury. Ann N Y Acad Sci. 2019 Feb;1437(1):43-56. doi:10.1111/nyas.13985. Epub 2018 Nov 29.Perrin P, Collongues N, Baloglu S, et al. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurol. 2021 Jan;28(1):248-58. doi:10.1111/ene.14491. Epub 2020 Oct 5.Perrin P, Collongues N, Baloglu S, et al. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurol. 2021 Jan;28(1):248-58. doi:10.1111/ene.14491. Epub 2020 Oct 5.Aceti A, Margarucci LM, Scaramucci E, et al. Serum S100B protein as a marker of severity in COVID-19 patients. Sci Rep. 2020 Oct 29;10(1):18665. doi:10.1038/s41598-020-75618-0Aceti A, Margarucci LM, Scaramucci E, et al. Serum S100B protein as a marker of severity in COVID-19 patients. Sci Rep. 2020 Oct 29;10(1):18665. doi:10.1038/s41598-020-75618-0Pilotto A, Masciocchi S, Volonghi I, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clin Infect Dis. 2021 Nov 2;73(9):e3019-e3026. doi:10.1093/cid/ciaa1933Pilotto A, Masciocchi S, Volonghi I, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clin Infect Dis. 2021 Nov 2;73(9):e3019-e3026. doi:10.1093/cid/ciaa1933Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi:10.1016/S2213-2600(20)30216-2. Epub 2020 Apr 27.Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi:10.1016/S2213-2600(20)30216-2. Epub 2020 Apr 27.Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. doi:10.1186/s40779-020-00240-0Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. doi:10.1186/s40779-020-00240-0Liu CC, Liu CC, Kanekiyo T, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013 Feb;9(2):106-18. doi:10.1038/nrneurol.2012.263. Epub 2013 Jan 8. Erratum in: Nat Rev Neurol. 2013. doi:10.1038/nmeurol.2013.32Liu CC, Liu CC, Kanekiyo T, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013 Feb;9(2):106-18. doi:10.1038/nrneurol.2012.263. Epub 2013 Jan 8. Erratum in: Nat Rev Neurol. 2013. doi:10.1038/nmeurol.2013.32Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2231-2. doi:10.1093/gerona/glaa131Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2231-2. doi:10.1093/gerona/glaa131Motta C, Finardi A, Toniolo S, et al. Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease Carrying Apolipoprotein E4 Genotype. J Alzheimers Dis. 2020;76(2):681-9. doi:10.3233/JAD-191250Motta C, Finardi A, Toniolo S, et al. Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease Carrying Apolipoprotein E4 Genotype. J Alzheimers Dis. 2020;76(2):681-9. doi:10.3233/JAD-191250Li J, Long X, Huang H, et al. Resilience of Alzheimer's Disease to COVID-19. J Alzheimers Dis. 2020;77(1):67-73. doi:10.3233/JAD-200649Li J, Long X, Huang H, et al. Resilience of Alzheimer's Disease to COVID-19. J Alzheimers Dis. 2020;77(1):67-73. doi:10.3233/JAD-200649Kurki SN, Kantonen J, Kaivola K, et al. APOE ε4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study. Acta Neuropathol Commun. 2021 Dec 23;9(1):199. doi:10.1186/s40478-021-01302-7Kurki SN, Kantonen J, Kaivola K, et al. APOE ε4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study. Acta Neuropathol Commun. 2021 Dec 23;9(1):199. doi:10.1186/s40478-021-01302-7Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol. 2014 Oct;50(2):534-44. doi:10.1007/s12035-014-8657-1. Epub 2014 Feb 25.Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol. 2014 Oct;50(2):534-44. doi:10.1007/s12035-014-8657-1. Epub 2014 Feb 25.Rachal Pugh C, Fleshner M, Watkins LR, et al. The immune system and memory consolidation: a role for the cytokine IL-1beta. Neurosci Biobehav Rev. 2001 Jan;25(1):29-41. doi:10.1016/s0149-7634(00)00048-8Rachal Pugh C, Fleshner M, Watkins LR, et al. The immune system and memory consolidation: a role for the cytokine IL-1beta. Neurosci Biobehav Rev. 2001 Jan;25(1):29-41. doi:10.1016/s0149-7634(00)00048-8Sheng JG, Ito K, Skinner RD, et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996 SepOct;17(5):761-6. doi:10.1016/0197-4580(96)00104-2Sheng JG, Ito K, Skinner RD, et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996 SepOct;17(5):761-6. doi:10.1016/0197-4580(96)00104-2Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD006378. doi:10.1002/14651858.CD006378.pub2Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD006378. doi:10.1002/14651858.CD006378.pub2Cani I, Barone V, D'Angelo R, et al. Frontal encephalopathy related to hyperinflammation in COVID-19. J Neurol. 2021 Jan;268(1):16-9. doi:10.1007/s00415-020-10057-5. Epub 2020 Jul 11.Cani I, Barone V, D'Angelo R, et al. Frontal encephalopathy related to hyperinflammation in COVID-19. J Neurol. 2021 Jan;268(1):16-9. doi:10.1007/s00415-020-10057-5. Epub 2020 Jul 11.Delorme C, Paccoud O, Kas A, et al; CoCo-Neurosciences study group and COVID SMIT PSL study group. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol. 2020 Dec;27(12):2651-7. doi:10.1111/ene.14478. Epub 2020 Sep 22.Delorme C, Paccoud O, Kas A, et al; CoCo-Neurosciences study group and COVID SMIT PSL study group. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol. 2020 Dec;27(12):2651-7. doi:10.1111/ene.14478. Epub 2020 Sep 22.Kas A, Soret M, Pyatigoskaya N, et al; on the behalf of CoCo-Neurosciences study group and COVID SMIT PSL study group. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2543-57. doi:10.1007/s00259-020-05178-y. Epub 2021 Jan 15. Erratum in: Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3304.Kas A, Soret M, Pyatigoskaya N, et al; on the behalf of CoCo-Neurosciences study group and COVID SMIT PSL study group. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2543-57. doi:10.1007/s00259-020-05178-y. Epub 2021 Jan 15. Erratum in: Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3304.Toniolo S, Di Lorenzo F, Scarioni M, et al. Is the Frontal Lobe the Primary Target of SARS-CoV-2? J Alzheimers Dis. 2021;81(1):75-81. doi:10.3233/JAD-210008Toniolo S, Di Lorenzo F, Scarioni M, et al. Is the Frontal Lobe the Primary Target of SARS-CoV-2? J Alzheimers Dis. 2021;81(1):75-81. doi:10.3233/JAD-210008Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020 Jun 4;382(23):2268-70. doi:10.1056/NEJMc2008597. Epub 2020 Apr 15.Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020 Jun 4;382(23):2268-70. doi:10.1056/NEJMc2008597. Epub 2020 Apr 15.Muccioli L, Pensato U, Cani I, et al. COVID-19-Associated Encephalopathy and Cytokine-Mediated Neuroinflammation. Ann Neurol. 2020 Oct;88(4):860-1. doi:10.1002/ana.25855. Epub 2020 Aug 14.Muccioli L, Pensato U, Cani I, et al. COVID-19-Associated Encephalopathy and Cytokine-Mediated Neuroinflammation. Ann Neurol. 2020 Oct;88(4):860-1. doi:10.1002/ana.25855. Epub 2020 Aug 14.Beaud V, Crottaz-Herbette S, Dunet V, et al. Pattern of cognitive deficits in severe COVID-19. J Neurol Neurosurg Psychiatry. 2021 May;92(5):567-8. doi:10.1136/jnnp-2020-325173. Epub 2020 Nov 20.Beaud V, Crottaz-Herbette S, Dunet V, et al. Pattern of cognitive deficits in severe COVID-19. J Neurol Neurosurg Psychiatry. 2021 May;92(5):567-8. doi:10.1136/jnnp-2020-325173. Epub 2020 Nov 20.Antony AR, Haneef Z. Systematic review of EEG findings in 617 patients diagnosed with COVID-19. Seizure. 2020 Dec;83:234-41. doi:10.1016/j.seizure.2020.10.014. Epub 2020 Oct 19.Antony AR, Haneef Z. Systematic review of EEG findings in 617 patients diagnosed with COVID-19. Seizure. 2020 Dec;83:234-41. doi:10.1016/j.seizure.2020.10.014. Epub 2020 Oct 19.Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, et al. 18FDG PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19. Acad Radiol. 2020 Jul;27(7):1042-3. doi:10.1016/j.acra.2020.04.030. Epub 2020 May 3.Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, et al. 18FDG PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19. Acad Radiol. 2020 Jul;27(7):1042-3. doi:10.1016/j.acra.2020.04.030. Epub 2020 May 3.O'Reilly RC. The What and How of prefrontal cortical organization. Trends Neurosci. 2010 Aug;33(8):355-61. doi:10.1016/j.tins.2010.05.002. Epub 2010 Jun 22.O'Reilly RC. The What and How of prefrontal cortical organization. Trends Neurosci. 2010 Aug;33(8):355-61. doi:10.1016/j.tins.2010.05.002. Epub 2010 Jun 22.Zhou H, Lu S, Chen J, et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020 Oct;129:98-102. doi:10.1016/j.jpsychires.2020.06.022. Epub 2020 Jun 30.Zhou H, Lu S, Chen J, et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020 Oct;129:98-102. doi:10.1016/j.jpsychires.2020.06.022. Epub 2020 Jun 30.Vintimilla R, Hall J, Johnson L, O'Bryant S. The relationship of CRP and cognition in cognitively normal older Mexican Americans: A cross-sectional study of the HABLE cohort. Medicine (Baltimore). 2019 May;98(19):e15605. doi:10.1097/MD.0000000000015605Vintimilla R, Hall J, Johnson L, O'Bryant S. The relationship of CRP and cognition in cognitively normal older Mexican Americans: A cross-sectional study of the HABLE cohort. Medicine (Baltimore). 2019 May;98(19):e15605. doi:10.1097/MD.0000000000015605Chiricosta L, Gugliandolo A, Mazzon E. SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer's Disease Patients. Int J Mol Sci. 2021 Dec 19;22(24):13603. doi:10.3390/ijms222413603Chiricosta L, Gugliandolo A, Mazzon E. SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer's Disease Patients. Int J Mol Sci. 2021 Dec 19;22(24):13603. doi:10.3390/ijms222413603Harker RC, Priemer DS. Beta-Amyloid Deposits in Young COVID Patients. Available from: https://ssrn.com/abstract=4003213 (accessed 25.04.2022).Harker RC, Priemer DS. Beta-Amyloid Deposits in Young COVID Patients. Available from: https://ssrn.com/abstract=4003213 (accessed 25.04.2022).Wang C, Pan R, Wan X, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020 Mar 6;17(5):1729. doi:10.3390/ijerph17051729Wang C, Pan R, Wan X, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020 Mar 6;17(5):1729. doi:10.3390/ijerph17051729Amjad H, Roth DL, Samus QM, et al. Potentially Unsafe Activities and Living Conditions of Older Adults with Dementia. J Am Geriatr Soc. 2016 Jun;64(6):1223-32. doi:10.1111/jgs.14164. Epub 2016 Jun 2.Amjad H, Roth DL, Samus QM, et al. Potentially Unsafe Activities and Living Conditions of Older Adults with Dementia. J Am Geriatr Soc. 2016 Jun;64(6):1223-32. doi:10.1111/jgs.14164. Epub 2016 Jun 2.Ammar A, Boukhris O, Halfpaap N, et al. Four Weeks of Detraining Induced by COVID-19 Reverse Cardiac Improvements from Eight Weeks of Fitness-Dance Training in Older Adults with Mild Cognitive Impairment. Int J Environ Res Public Health. 2021 May 31;18(11):5930. doi:10.3390/ijerph18115930Ammar A, Boukhris O, Halfpaap N, et al. Four Weeks of Detraining Induced by COVID-19 Reverse Cardiac Improvements from Eight Weeks of Fitness-Dance Training in Older Adults with Mild Cognitive Impairment. Int J Environ Res Public Health. 2021 May 31;18(11):5930. doi:10.3390/ijerph18115930World Health Organization et al. World Health Organization Global recommendations on physical activity for health. Geneva, Switzerland: WHO; 2010. International Journal of Movement Science and Rehabilitation. ISSN-2674-9181World Health Organization et al. World Health Organization Global recommendations on physical activity for health. Geneva, Switzerland: WHO; 2010. International Journal of Movement Science and Rehabilitation. ISSN-2674-9181Qin F, Song Y, Nassis GP, et al. Prevalence of insufficient physical activity, sedentary screen time and emotional well-being during the early days of the 2019 novel coronavirus (COVID-19) outbreak in China: a national cross-sectional study. SSRN Electron J. Jan 2020. doi:10.2139/ssrn.3566176Qin F, Song Y, Nassis GP, et al. Prevalence of insufficient physical activity, sedentary screen time and emotional well-being during the early days of the 2019 novel coronavirus (COVID-19) outbreak in China: a national cross-sectional study. SSRN Electron J. Jan 2020. doi:10.2139/ssrn.3566176Lara B, Carnes A, Dakterzada F, et al. Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer's disease during the COVID-19 lockdown. Eur J Neurol. 2020;27(9):1744-7. doi:10.1111/ene.14339. Epub 25 May 2020.Lara B, Carnes A, Dakterzada F, et al. Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer's disease during the COVID-19 lockdown. Eur J Neurol. 2020;27(9):1744-7. doi:10.1111/ene.14339. Epub 25 May 2020.Canevelli M, Valletta M, Toccaceli Blasi M, et al. Facing Dementia During the COVID-19 Outbreak. J Am Geriatr Soc. 2020 Aug;68(8):1673-6. doi:10.1111/jgs.16644. Epub 2020 Jun 9.Canevelli M, Valletta M, Toccaceli Blasi M, et al. Facing Dementia During the COVID-19 Outbreak. J Am Geriatr Soc. 2020 Aug;68(8):1673-6. doi:10.1111/jgs.16644. Epub 2020 Jun 9.Vernuccio L, Sara D, Inzerillo F, et al. Effect of COVID-19 quarantine on cognitive, functional and neuropsychiatric symptoms in patients with mild cognitive impairment and dementia. Aging Clin Exp Res. 2022 May;34(5):1187-94. doi:10.1007/s40520-022-02113-z. Epub 2022 Mar 24.Vernuccio L, Sara D, Inzerillo F, et al. Effect of COVID-19 quarantine on cognitive, functional and neuropsychiatric symptoms in patients with mild cognitive impairment and dementia. Aging Clin Exp Res. 2022 May;34(5):1187-94. doi:10.1007/s40520-022-02113-z. Epub 2022 Mar 24.Cudjoe TKM, Kotwal AA. “Social Distancing” Amid a Crisis in Social Isolation and Loneliness. J Am Geriatr Soc. 2020 Jun;68(6):E27-E29. doi:10.1111/jgs.16527. Epub 2020 May 15.Cudjoe TKM, Kotwal AA. “Social Distancing” Amid a Crisis in Social Isolation and Loneliness. J Am Geriatr Soc. 2020 Jun;68(6):E27-E29. doi:10.1111/jgs.16527. Epub 2020 May 15.Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008 Sep 3;300(9):1027-37. doi:10.1001/jama.300.9.1027. Erratum in: JAMA. 2009 Jan 21;301(3):276.Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008 Sep 3;300(9):1027-37. doi:10.1001/jama.300.9.1027. Erratum in: JAMA. 2009 Jan 21;301(3):276.Nagamatsu LS, Handy TC, Hsu CL, et al. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. Arch Intern Med. 2012 Apr 23;172(8):666-8. doi:10.1001/archinternmed.2012.379. Erratum in: Arch Intern Med. 2013 Aug 12;173(15):1477.Nagamatsu LS, Handy TC, Hsu CL, et al. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. Arch Intern Med. 2012 Apr 23;172(8):666-8. doi:10.1001/archinternmed.2012.379. Erratum in: Arch Intern Med. 2013 Aug 12;173(15):1477.Varela S, Ayan C, Cancela JM, Martin V. Effects of two different intensities of aerobic exercise on elderly people with mild cognitive impairment: a randomized pilot study. Clin Rehabil. 2012 May;26(5):442-50. doi:10.1177/0269215511425835. Epub 2011 Nov 24.Varela S, Ayan C, Cancela JM, Martin V. Effects of two different intensities of aerobic exercise on elderly people with mild cognitive impairment: a randomized pilot study. Clin Rehabil. 2012 May;26(5):442-50. doi:10.1177/0269215511425835. Epub 2011 Nov 24.Suzuki T, Shimada H, Makizako H, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PLoS One. 2013 Apr 9;8(4):e61483. doi:10.1371/journal.pone.0061483Suzuki T, Shimada H, Makizako H, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PLoS One. 2013 Apr 9;8(4):e61483. doi:10.1371/journal.pone.0061483Rehfeld K, Lüders A, Hökelmann A, et al. Dance training is superior to repetitive physical exercise in inducing brain plasticity in the elderly. PLoS One. 2018 Jul 11;13(7):e0196636. doi:10.1371/journal.pone.0196636Rehfeld K, Lüders A, Hökelmann A, et al. Dance training is superior to repetitive physical exercise in inducing brain plasticity in the elderly. PLoS One. 2018 Jul 11;13(7):e0196636. doi:10.1371/journal.pone.0196636Chaabene H, Prieske O, Herz M, et al. Home-based exercise programmes improve physical fitness of healthy older adults: A PRISMA-compliant systematic review and meta-analysis with relevance for COVID-19. Ageing Res Rev. 2021 May;67:101265. doi:10.1016/j.arr.2021.101265. Epub 2021 Feb 8.Chaabene H, Prieske O, Herz M, et al. Home-based exercise programmes improve physical fitness of healthy older adults: A PRISMA-compliant systematic review and meta-analysis with relevance for COVID-19. Ageing Res Rev. 2021 May;67:101265. doi:10.1016/j.arr.2021.101265. Epub 2021 Feb 8.Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции: руководство для врачей. Москва: МЕДпресс-информ; 2010. 272 с.Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii: rukovodstvo dlya vrachey [Dementia: a guide for physicians]. Moscow: MEDpressinform; 2010. 272 p. (In Russ.)Гаврилова СИ. Фармакотерапия болезни Альцгеймера. Москва: Пульс; 2003. 319 с.Gavrilova SI. Farmakoterapiya bolezni Al’tsgeymera [Pharmacotherapy of Alzheimer's disease]. Moscow: Pul’s; 2003. 319 p. (In Russ.)Bonfoco E, Krainc D, Ankarcrona M, et al. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7162-6. doi:10.1073/pnas.92.16.7162Bonfoco E, Krainc D, Ankarcrona M, et al. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7162-6. doi:10.1073/pnas.92.16.7162Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine – results of a phase II double-blind study. Pharmacopsychiatry. 1988 May;21(3):144-6. doi:10.1055/s-2007-1014666Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine – results of a phase II double-blind study. Pharmacopsychiatry. 1988 May;21(3):144-6. doi:10.1055/s-2007-1014666Reisberg B, Doody R, Stöffler A, et al; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41. doi:10.1056/NEJMoa013128Reisberg B, Doody R, Stöffler A, et al; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41. doi:10.1056/NEJMoa013128Van Dyck CH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry. 2006 May;14(5):428-37. doi:10.1097/01.JGP.0000203151.17311.38Van Dyck CH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry. 2006 May;14(5):428-37. doi:10.1097/01.JGP.0000203151.17311.38Успенская ОВ, Яхно НН. Влияние мемантина на когнитивные функции пациентов с амнестическим вариантом синдрома умеренных когнитивных расстройств (клинико-психологическое и нейрохимическое исследование). Неврологический журнал. 2009;14(3):49-54.Uspenskaya OV, Yakhno NN. The effect of memantine on the cognitive functions of patients with the amnesic variant of the syndrome of moderate cognitive impairment (clinical-psychological and neurochemical study). Nevrologicheskiy zhurnal. 2009;14(3):49-54 (In Russ.)Яхно НН, Преображенская ИС, Захаров ВВ и др. Эффективность Акатинола Мемантина у пациентов с недементными когнитивными расстройствами. Результаты многоцентрового клинического наблюдения. Неврологический журнал. 2010;15(2):52-8.Yakhno NN, Preobrazhenskaya IS, Zakharov VV, et al. Efficacy of Akatinol Memantine in patients with non-dementia cognitive disorders. Results of multicenter clinical observation. Nevrologicheskiy zhurnal. 2010;15(2):52-8 (In Russ.)Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008 Mar;69(3):341-8. doi:10.4088/jcp.v69n0302Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008 Mar;69(3):341-8. doi:10.4088/jcp.v69n0302Brenner SR. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. J Med Virol. 2020 Nov;92(11):2341-2. doi:10.1002/jmv.26030. Epub 2020 Jun 2.Brenner SR. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. J Med Virol. 2020 Nov;92(11):2341-2. doi:10.1002/jmv.26030. Epub 2020 Jun 2.Balli N, Kara E, Demirkan K. The another side of COVID-19 in Alzheimer's disease patients: Drug-drug interactions. Int J Clin Pract. 2020 Oct;74(10):e13596. doi:10.1111/ijcp.13596Balli N, Kara E, Demirkan K. The another side of COVID-19 in Alzheimer's disease patients: Drug-drug interactions. Int J Clin Pract. 2020 Oct;74(10):e13596. doi:10.1111/ijcp.13596

The authors declare that there are no conflicts of interest present.